Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Frytak

Showing results (51-60 of 110) with videos related to

Pageof 11
Sort By:
Cancer Treatment Reports|May 1, 1986
Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patientsE T Creagan, D L Ahmann, S Frytak, et al.
Cancer Treatment Reports|February 1, 1987
Phase II study of recombinant gamma-interferon in patients with advanced nonosseous sarcomasJ H Edmonson, H J Long, E T Creagan, et al.
American Journal of Clinical Oncology|June 1, 1986
Differing response rates and survival between squamous and non-squamous non-small cell lung cancer. Comparison of CAP versus MAPR T Eagan, S Frytak, E T Creagan, et al.
Cancer Treatment Reports|November 1, 1976
Phase II study of VP-16-213 versus dianhydrogalactitol in patients with metastatic malignant melanomaD L Ahmann, H F Bisel, J H Edmonson, et al.
Cancer|February 1, 1987
Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analysesE T Creagan, D L Ahmann, S Frytak, et al.
Cancer Treatment Reports|August 1, 1980
Phase II evaluation of the combination of triazinate, cyclophosphamide, doxorubicin, and cis-diamminedichloroplatinum(II) in patients with advanced adenocarcinoma of the lungR T Eagan, S Frytak, J N Ingle, et al.
Cancer|March 1, 1976
A phase I study of cytembenaS Frytak, C G Moertel, A J Schutt, et al.
Cancer Treatment Reports|May 1, 1981
Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancersR T Eagan, S Frytak, W C Nichols, et al.
American Journal of Clinical Oncology|April 1, 1987
No routine role for vincristine, adriamycin, and cyclophosphamide (VAC) or thoracic radiation therapy in extensive stage small cell lung cancerR T Eagan, S Frytak, R E Lee, et al.
Cancer Treatment Reports|September 1, 1979
Phase II study of cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum (II) by infusion in patients with adenocarcinoma and large cell carcinoma of the lungR T Eagan, S Frytak, E T Creagan, et al.
Pageof 11

Showing results (51-60 of 110) with videos related to

Sort By:
Pageof 11
Cancer Treatment Reports|May 1, 1986
Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patientsE T Creagan, D L Ahmann, S Frytak, et al.
Cancer Treatment Reports|February 1, 1987
Phase II study of recombinant gamma-interferon in patients with advanced nonosseous sarcomasJ H Edmonson, H J Long, E T Creagan, et al.
American Journal of Clinical Oncology|June 1, 1986
Differing response rates and survival between squamous and non-squamous non-small cell lung cancer. Comparison of CAP versus MAPR T Eagan, S Frytak, E T Creagan, et al.
Cancer Treatment Reports|November 1, 1976
Phase II study of VP-16-213 versus dianhydrogalactitol in patients with metastatic malignant melanomaD L Ahmann, H F Bisel, J H Edmonson, et al.
Cancer|February 1, 1987
Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analysesE T Creagan, D L Ahmann, S Frytak, et al.
Cancer Treatment Reports|August 1, 1980
Phase II evaluation of the combination of triazinate, cyclophosphamide, doxorubicin, and cis-diamminedichloroplatinum(II) in patients with advanced adenocarcinoma of the lungR T Eagan, S Frytak, J N Ingle, et al.
Cancer|March 1, 1976
A phase I study of cytembenaS Frytak, C G Moertel, A J Schutt, et al.
Cancer Treatment Reports|May 1, 1981
Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancersR T Eagan, S Frytak, W C Nichols, et al.
American Journal of Clinical Oncology|April 1, 1987
No routine role for vincristine, adriamycin, and cyclophosphamide (VAC) or thoracic radiation therapy in extensive stage small cell lung cancerR T Eagan, S Frytak, R E Lee, et al.
Cancer Treatment Reports|September 1, 1979
Phase II study of cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum (II) by infusion in patients with adenocarcinoma and large cell carcinoma of the lungR T Eagan, S Frytak, E T Creagan, et al.
Pageof 11